Skip to main content

Branded Legacy, Inc. Partners with McMaster University: Revolutionizing Addiction Treatment Through Cutting-Edge Clinical Research and Regulatory Pathways

Written by Customer Service on . Posted in Public Companies.

Acquisition Poised to Accelerate Life-Saving Interventions, Combining Academic Excellence with Real-World Innovation to Address Global Addiction Crises and Unlock Multi-Billion Market Opportunities

VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) — via IBN — Branded Legacy, Inc. (OTC: BLEG), a leading diversified holdings company dedicated to pioneering health and wellness solutions, today announced a groundbreaking strategic partnership between its wholly-owned subsidiary, Bio-Legacy Evaluative Group, and McMaster University, one of the world’s top medical universities renowned for its influential research in addiction medicine, clinical trials, and guideline development at state, provincial, national, and international levels. This collaboration will focus on evaluating Bio-Legacy Evaluative Group’s innovative products for populations affected by addictions, leveraging McMaster’s expertise in groundbreaking research and its access to world leaders in the field.

The partnership unites the clinical research prowess of McMaster University with the real-world experience of Bio-Legacy Evaluative Group’s scientists in addictions medicine, paving the way for rigorous evaluations, multiple clinical trials, and regulatory submissions for Bio-Legacy Evaluative Group’s drug devices and new compounds. This alliance is set to drive the development of accessible, cost-effective interventions that address acute overdose deaths, minimize drug-related harms, and support long-term recovery for addicted populations.

Professor Ed Mills of McMaster University commented, “The collaboration between Bio-Legacy Evaluative Group and the faculty here allows us to further our deep commitment to addressing the needs for treatments in addictions and the rigorous evaluations of interventions that can save lives. In addition to the many clinical research projects at McMaster University and the enormous populations we work with that are affected by addictions, these populations also have a long history of collaboration with researchers ensuring we have access to the people needed for meaningful clinical research.”

Amin Janmohamed, CEO of Branded Legacy, Inc., stated, “This partnership marks a pivotal step for our subsidiary, Bio-Legacy Evaluative Group, as we enter into drug development and the need for rigorous evaluations of the drugs and interventions we develop. Few universities are as well recognized for their expertise in clinical research and methodology as McMaster University, and this partnership will lead to multiple clinical trials and evaluations needed for submission to regulators. The intellectual rigour created through this partnership is outstanding.”

At the heart of Bio-Legacy Evaluative Group’s mission, under the strategic oversight of Branded Legacy, Inc., is the creation of new interventions that save lives quickly for those impacted by addictions—starting with preventing acute deaths through overdose, reducing harms from drug use, and ultimately helping individuals achieve reduced dependency. Together, Bio-Legacy Evaluative Group and McMaster University are committed to building interventions that can be developed rapidly, affordably, and accessibly for the populations in greatest need, scaling from local innovation to global impact.

Bio-Legacy Evaluative Group’s flagship product exemplifies this approach: a patented all-in-one intranasal naloxone delivery device that introduces a novel strategy to meet the evolving needs of opioid-addicted populations. This technology overcomes critical market limitations, such as high costs, inconsistent dosing, and cumbersome systems, by streamlining manufacturing and improving dose precision. Amid a naloxone market projected to surge from $371 million in 2022 to over $1.16 billion by 2032 at a CAGR of approximately 11.9%, this partnership positions Bio-Legacy Evaluative Group, under Branded Legacy, Inc., to capture significant share through enhanced clinical validation and regulatory pathways.

By combining McMaster’s scientific rigor with Bio-Legacy Evaluative Group’s embedded knowledge in North American and global addiction communities, the partnership establishes a scalable industry model that meets regulatory and buyer requirements with both academic expertise and practical insights. This collaboration not only addresses pressing societal needs but also fuels long-term growth for Branded Legacy, Inc., enhancing shareholder value through innovative, life-saving advancements.

About Branded Legacy, Inc.

Branded Legacy, Inc. (OTC: BLEG) is a holdings company focused on health and wellness, developing innovative solutions to combat addiction by preventing overdoses and supporting recovery. Its patented intranasal naloxone delivery device enhances accessibility and dosing precision for opioid overdose treatment. The platform also enables nasal delivery of vaccines and other medications, opening opportunities in global markets for rapid pandemic response and improved access in underserved regions, driving shareholder value.

Investor Relations:
Branded Legacy, Inc. 
Email: info@brandedlegacy.com
Phone: 877-250-9077

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.